Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles Journal of Neurology, Neurosurgery and Psychiatry Year : 2021

Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications

Philippe Couratier
  • Function : Author
Claire Boutoleau-Bretonnière
  • Function : Author
  • PersonId : 1290711
  • IdRef : 073681458
Jérémie Pariente
Isabelle Le Ber
  • Function : Author
  • PersonId : 889822

Abstract

Objective Neurofilament light chain (NfL) is a promising biomarker in genetic frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We evaluated plasma neurofilament light chain (pNfL) levels in controls, and their longitudinal trajectories in C9orf72 and GRN cohorts from presymptomatic to clinical stages. Methods We analysed pNfL using Single Molecule Array (SiMoA) in 668 samples (352 baseline and 316 follow-up) of C9orf72 and GRN patients, presymptomatic carriers (PS) and controls aged between 21 and 83. They were longitudinally evaluated over a period of >2 years, during which four PS became prodromal/ symptomatic. Associations between pNfL and clinicalgenetic variables, and longitudinal NfL changes, were investigated using generalised and linear mixed-effects models. Optimal cutoffs were determined using the Youden Index. Results pNfL levels increased with age in controls, from ~5 to~18 pg/mL (p<0.0001), progressing over time (mean annualised rate of change (ARC): +3.9%/year, p<0.0001). Patients displayed higher levels and greater longitudinal progression (ARC: +26.7%, p<0.0001), with gene-specific trajectories. GRN patients had higher levels than C9orf72 (86.21 vs 39.49 pg/mL, p=0.014), and greater progression rates (ARC:+29.3% vs +24.7%; p=0.016). In C9orf72 patients, levels were associated with the phenotype (ALS: 71.76 pg/mL, FTD: 37.16, psychiatric: 15.3; p=0.003) and remarkably lower in slowly progressive patients (24.11, ARC: +2.5%; p=0.05). Mean ARC was +3.2% in PS and +7.3% in prodromal carriers. We proposed gene-specific cutoffs differentiating patients from controls by decades. Conclusions This study highlights the importance of gene-specific and age-specific references for clinical and therapeutic trials in genetic FTD/ALS. It supports the usefulness of repeating pNfL measurements and considering ARC as a prognostic marker of disease progression. Trial registration numbers NCT02590276 and NCT04014673.

Domains

Neurobiology
Fichier principal
Vignette du fichier
jnnp-2021-326914.full.pdf (4.68 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03337055 , version 1 (07-09-2021)

Identifiers

Cite

Dario Saracino, Karim Dorgham, Agnès Camuzat, Daisy Rinaldi, Armelle Rametti-Lacroux, et al.. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92 (12), pp.1278-1288. ⟨10.1136/jnnp-2021-326914⟩. ⟨hal-03337055⟩
70 View
46 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More